We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Alternative to Animal-sourced Heparins Set for Clinical Trials

News   Sep 07, 2017 | Original story written by Mary L. Martialay for the Rensselaer Polytechnic Institute

 
Synthetic Alternative to Animal-sourced Heparins Set for Clinical Trials

Synthetic low molecular weight heparin proven safe and effective in preclinical trials. Credit: Rensselaer Polytechnic Institute

 
 
 

RELATED ARTICLES

Cellular “Garbage” No More — Exosomes Show Potential in Treating and Diagnosing Brain Disorders

News

Once simply thought to be microscopic sacks of cellular “garbage”, exosomes are now understood to hold immense importance for our health. In a new study, researchers show that exosomes are not only integral to the development of neurons and neural circuits, but they can restore health to brain cells affected by developmental disease.

READ MORE

Targeting Enzyme “Bottleneck” Reveals Novel Anticancer Drug Strategy

News

The enzyme ribonucleotide reductase is a bottleneck for cancer cell growth. Scientists have now identified a way of targeting ribonucleotide reductase that may avoid the toxicity of previous approaches, informing focused drug discovery efforts.

READ MORE

Compound Created to Block Therapeutic Target in Blood Cancer

News

Researchers have discovered a hyperactive cell signal that contributes to tumor growth in an aggressive blood cancer. The team has also developed an experimental therapeutic "UNC3810A" to block the signal and slow tumor growth.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE